Literature DB >> 7969986

Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism.

R Furie1, T Ishikawa, V Dhawan, D Eidelberg.   

Abstract

We used 18F-fluorodeoxyglucose and PET to study a 23-year-old woman with alternating hemichorea and primary antiphospholipid syndrome. There were three PET studies: (1) during an episode of right hemichorea, (2) during an asymptomatic period 6 months later, and (3) during an episode of left hemichorea occurring 2 months after that. In each study, we calculated normalized regional glucose metabolism for the caudate and lentiform nuclei and compared these values with those calculated in 12 normal volunteer subjects (mean age, 35.3 +/- 9.0). The following results were obtained: (1) during right hemichorea, left lentiform metabolism was increased by 19% (> 3 SD); (2) during the asymptomatic period, right caudate metabolism was increased by 20% (> 3 SD), and right lentiform and left striatal metabolism were normal; and (3) during left hemichorea, right caudate and lentiform metabolism were both elevated by 33% (> 3 SD). During this episode, left caudate metabolism was elevated by 20% (> 2 SD); left lentiform metabolism was normal. These results suggest that hemichorea in primary antiphospholipid syndrome may be associated with contralateral striatal hypermetabolism that may also be present during asymptomatic periods.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969986     DOI: 10.1212/wnl.44.11.2197

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

2.  Striatal hypermetabolism in limbic encephalitis.

Authors:  Caroline Rey; Lejla Koric; Eric Guedj; Olivier Felician; Elsa Kaphan; José Boucraut; Mathieu Ceccaldi
Journal:  J Neurol       Date:  2011-11-12       Impact factor: 4.849

3.  A case report of paroxysmal dystonic choreoathetosis due to hypoglycaemia induced by an insulinoma.

Authors:  C Shaw; L Haas; D Miller; J Delahunt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 4.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

5.  Reversible striatal hypermetabolism in chorea associated with moyamoya disease: a report of two cases.

Authors:  Yoshito Sugita; Takeshi Funaki; Jun C Takahashi; Yasushi Takagi; Yasutaka Fushimi; Takayuki Kikuchi; Kazumichi Yoshida; Taketo Hatano; Natsuhi Sasaki; Susumu Miyamoto
Journal:  Childs Nerv Syst       Date:  2016-05-18       Impact factor: 1.475

6.  Change in striatal metabolism in diabetic haemichorea-haemiballism.

Authors:  Takao Hashimoto; Kazuhiro Oguchi; Ryo Takeuchi
Journal:  BMJ Case Rep       Date:  2012-09-24

7.  Hemichorea with antiphospholipid antibodies in a patient with lupus nephritis.

Authors:  Toru Watanabe; Hiroo Onda
Journal:  Pediatr Nephrol       Date:  2004-01-23       Impact factor: 3.714

Review 8.  Unusual manifestations of the antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

9.  Corticostriatal Hypermetabolism in Moyamoya Disease-Induced Hemichorea: Two Case Reports and a Literature Review.

Authors:  Wen-Biao Xian; Xiang-Song Zhang; Xin-Chong Shi; Gan-Hua Luo; Chang Yi; Zhong Pei
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

10.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.